Three decades of messenger RNA vaccine development

  title={Three decades of messenger RNA vaccine development},
  author={Rein Verbeke and Ine Lentacker and Stefaan De Smedt and Heleen Dewitte},
  journal={Nano Today},

Figures and Tables from this paper

mRNA vaccines for infectious diseases: principles, delivery and clinical translation

The technologies that underlie mRNA vaccines are described, with an emphasis on lipid nanoparticles and other non-viral delivery vehicles, and the pipeline of mRNA vaccines against various infectious disease pathogens is overview.

pDNA and mRNA vaccines

  • Kanwal Gill
  • Biology
    Practical Aspects of Vaccine Development
  • 2022

The Delivery of mRNA Vaccines for Therapeutics

The recent progress in the delivery methods, modes of delivery and patentable mRNA vaccine technologies are reviewed.

Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases

This review aims to demystify mRNA vaccines, delineating the evolution of the technology which has emerged as a timely solution to COVID-19 and exploring the immense potential it offers as a prophylactic option for other cryptic diseases.

HIV mRNA Vaccines—Progress and Future Paths

This review discusses mRNA-based approaches for the generation of prophylactic and therapeutic vaccines to HIV, and examines the special immunological hurdles for a vaccine to elicit broadly neutralizing antibodies and effective T cell responses to HIV.

Self-assembled mRNA vaccines

The mRNA Vaccine Heralds a New Era in Vaccinology

How numerous innate response mechanisms are triggered by mRNA molecules, and how each element, from the 5' cap to the poly-A tail, interferes with innate/adaptive immune responses are highlighted.

The dawn of mRNA vaccines: The COVID-19 case




mRNA vaccines — a new era in vaccinology

A detailed overview of mRNA vaccines is provided and future directions and challenges in advancing this promising vaccine platform to widespread therapeutic use are considered.

A novel, disruptive vaccination technology

Initial clinical experiences suggest that the preclinical immunogenicity of RNActive® could be successfully translated to humans and protect against lethal challenges with a variety of different influenza strains in preclinical models.

Developing mRNA-vaccine technologies

Based on in situ protein expression, mRNA vaccines are capable of inducing a balanced immune response comprising both cellular and humoral immunity while not subject to MHC haplotype restriction and are an intrinsically safe vector.

Tools for translation: non-viral materials for therapeutic mRNA delivery

An overview of the field of mRNA therapeutics is provided and recent advances in the development of synthetic materials that encapsulate and deliver mRNA payloads are described.

mRNA-based therapeutics — developing a new class of drugs

This Review provides a comprehensive overview of the current state of mRNA-based drug technologies and their applications, and discusses the key challenges and opportunities in developing these into a new class of drugs.

mRNA: Fulfilling the Promise of Gene Therapy.

  • D. WeissmanK. Karikó
  • Biology
    Molecular therapy : the journal of the American Society of Gene Therapy
  • 2015
An alternative method for generating nonimmunogenic IVT mRNA that avoids the use of modified nucleosides is reported and it is demonstrated that sequence engineering of the mRNA and purifying it with high performance liquid chromatography are sufficient to avoid immune activation and to achieve high levels of translation of the encoded protein.

How mRNA therapeutics are entering the monoclonal antibody field

The potential of mRNA-based approaches to solve several of the issues associated with antibodies produced and delivered in protein format are highlighted and key hurdles that mRNA- based approaches still need to take are identified to fulfill this potential and ultimately replace the current protein antibody format.

Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses

mRNA mediates passive vaccination against infectious agents, toxins, and tumors

The utility of formulated mRNA as a potent novel technology for passive immunization is demonstrated, enabling both prophylactic and therapeutic protection against lethal rabies infection or botulinum intoxication.